EP0000931A1 - Enzymatic cleavage of N-acyl-thienamycins - Google Patents

Enzymatic cleavage of N-acyl-thienamycins Download PDF

Info

Publication number
EP0000931A1
EP0000931A1 EP78100699A EP78100699A EP0000931A1 EP 0000931 A1 EP0000931 A1 EP 0000931A1 EP 78100699 A EP78100699 A EP 78100699A EP 78100699 A EP78100699 A EP 78100699A EP 0000931 A1 EP0000931 A1 EP 0000931A1
Authority
EP
European Patent Office
Prior art keywords
thienamycin
acyl
process according
carbon atoms
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP78100699A
Other languages
German (de)
French (fr)
Other versions
EP0000931B1 (en
Inventor
Jean Sawyer Kahan
Frederick Marvin Kahan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0000931A1 publication Critical patent/EP0000931A1/en
Application granted granted Critical
Publication of EP0000931B1 publication Critical patent/EP0000931B1/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D477/00Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20Sulfur atoms

Definitions

  • the enzyme, penicillin amidohydrolase of bacterial or fungal origin is used on an industrial scale to catalyze the hydrolytic removal of the side chain of penicillin to give the nucleus 6-amino penicillanic acid (6-APA).
  • This nucleus is the starting material for the synthesis of broad spectrum penicillins (semisynthetic) which are prepared by acylation of the amino group.
  • a new antibiotic is thienamycin, (U.S. Patent No. 3,950,357).
  • the teachings of U.S. Patent No. 3,950,357 are incorporated herein by reference.
  • N-acyl derivatives of thienamycin are unexpectedly cleaved by penicillin amidohydrolase.
  • the present invention provides a new process for conversion of N-acyl-thienamycins to thienamycin.
  • N-acyl- thienamycin having the following structure: wherein R 1 and R 2 are independently selected from the group consisting of hydrogen (R and R 2 are not both hydrogen) or an acyl group is contacted in an aqueous medium with enzymes which are capable of removing the N-acyl moiety in order to form thienamycin.
  • Thienamycin has the structure: Thienamycin is a valuable antibiotic which is active against both gram-positive and gram-negative bacteria.
  • the enzymes utilized to remove the N-acyl moiety are penicillin amidohydrolases.
  • the preferred compounds of this invention are those wherein R 1 is hydrogen and R 2 is acyl.
  • acyl is meant the aliphatic and aromatic carboxylic acids including derivatives and analogs thereof such as thio analogs wherein the carbonyl oxygen is replaced by sulphur, diacyl radicals wherein R 1 and R 2 are joined together; as well as the sulphur and phosphorous acyl analogs such as substituted sulfonyl-, sulfinyl-, and sulfenyl-radicals, and substituted P(III) and P(V) radicals such as the substituted phosphorous-, phosphoric-, phosphonous- and phosphonic radicals, respectively.
  • Such acyl radicals of the present invention are further defined below.
  • the N-acyl derivatives may be prepared by any of the techniques well known in the art if the thienamycin has been isolated from the fermentation broth or solution. If the thienamycin has not been isolated from the fermentation broth, then the method of preparing the N-acyl-thienamycin is by reacting the appropriate acyl compound while the thienamycin is still in the broth or solution. Alternatively, the acyl group can be incorporated biosynthetically following supplementation of the fermentation broth with the parent acid or a derivative thereof. These derivatives, by virtue of their increased solubility in organic solvents and additional physical properties, provide alternate and more efficient routes for recovery of the thienamycin nucleus. Once the derivatized thienamycin is recovered from the broth or solution, it can be treated by the methods described in this invention in order to regenerate the thienamycin.
  • the acyl radical represented by either R 1 or R 2 can, inter alia, be substituted or unsubstituted aliphatic, aromatic or heterocyclic, araliphatic or heterocylylaliphatic carboxylic acid radical, a substituted or unsubstituted carbamyl radical or a carbothioic acid radical.
  • One group of acyl radicals can be represented by the general formula: wherein X is 0 or S and R" represents a straight or branched chain alkyl or alkoxymethylene group containing from 5-10 carbon atoms, aryloxymethylene, typically comprising 6-10 carbon atoms.
  • Such above-listed groups can be unsubstituted or can be substituted by radicals such as OH, SH, SR (R is i loweralkyl or aryl such as phenyl), alkyl or alkoxy groups having 1 to about 6 carbon atoms, halo, such as Cl, Br, F and I, cyano, carboxy, sulfamino, carbamoyl, sulfonyl, azido, amino, substituted amino such as alkylamino including quaternary ammonium wherein the alkyl group comprises 1-6 carbon atoms, haloalkyl such as trifluoromethyl, carboxyalkyl, carbamoylalkyl, N-substituted carbamoylalkyl, wherein the alkyl moiety of the foregoing four radicals comprises 1 to about 6 carbon atoms, amidino, guanidino, N-substituted guanidino, guanidino lower alkyl and
  • acyl groups that might be mentioned are those wherein R" is benzyl, phenoxymethylene, p-hydroxybenzyl, n-amyl, n-heptyl, 3- or 4-nitrobenzyl, phenethyl, ⁇ , ⁇ -diphenylethyl, methyldiphenylmethyl, triphenylmethyl, 2-methoxyphenyl, 2,6-dimethoxyphenyl, 2,4,6-trimethoxyphenyl, D-4-N-benzoylamino-4-carboxy-n-butyl, p-aminobenzyl, o-aminobenzyl, m-aminobenzyl, p-dimethylaminobenzyl, 2-ethoxy-l-napthyl, 4-guanidinomethylphenyl, 4-guanidinomethylbenzyl, 4-guanidinobenzyl, 4-guanidinophenyl, 2,6-dimethoxy-4-guanidino
  • the preferred compounds that can be utilized in this invention that fit the above acyl radical description are phenylacetyl, p-hydroxyphenylacetyl, phenylglycyl, 2-thienylacetyl, phenoxyacetyl, N-propoxyacetyl and iso-butoxyacetyl.
  • penicillin amidohydrolases to convert penicillins into 6-aminopenicillanic acid (6-APA) is known in the art.
  • penicillin amidohydrolases to remove the N-acyl side chains of N-acylated thienamycin is surprising.
  • the process of this invention may be conducted by reacting the starting material of the general formula I with the enzyme extract from a cultured broth, the filtrate or fermentation product of the Escherichia coli culture or a powder of the enzyme in an aqueous solution.
  • the enzyme may be immobilized by adsorption or chemical reaction to an insoluble supporting structure such as glass, cellulose or agarose, and used to hydrolyse the N-acylated thienamycin either by contacting it in suspension, or by the percolation of the acylated material through a bed of the immobilized enzyme preparation.
  • an insoluble supporting structure such as glass, cellulose or agarose
  • the enzyme is capable of removing N-acyl moietys which were present or produced in fermentation broths as well as those N-acyl groups introduced during isolation of the antibiotic or made by chemical synthesis techniques.
  • N-acylated thienamycin takes place in the presence of an enzyme of the microorganism of the genus Escherichia coli which is able to remove the acyl moiety to provide the antibiotic thienamycin.
  • the amidohydrolase enzyme For the production of the amidohydrolase enzyme by cultivation of the above-mentioned microorganism, there may be used various culture media commonly employed for the cultivation of a microorganism. More specifically, glucose, sucrose, glycerol, starch, oils used for cultivation and the like as a carbon source and peptone, buillion, corn steep liquor, yeast extract, meat extract, fish meal, defatted soybean, wheat embryo and the like as a nitrogen source may be employed. If required, other additives may be employed in combination with the above. It is an advantage but not a necessity to include phenylacetic acid or its salts or derivatives in fermentation media.
  • Escherichia coli is usually shaken or agitated under aeration.
  • Cultivation temperature may range from about 23-27°C.
  • Cultivation period is usually 20-28 hours.
  • amidohydrolase contained in the cultured broth or its extract may be utilized in the present process without any further purification.
  • the amidohydrolase enzyme may be precipitated with appropriate solvents, salted out or dialyzed or otherwise purified. It may be used free in solution or immobilized on an appropriat surface.
  • a method utilized in the present invention is that of utilizing the whole cell amidohydrolase preparation. By this method, after cultivation, the culture is centrifuged to obtain the whole cells for subsequent reaction with the derivatized thienamycin.
  • reaction mixtures are incubated 18 hours at 23°C.
  • the assay plates are prepared as follows: An overnight growth of the assay organism, Staphylococcus aureus ATCC 6538P, in nutrient broth plus 0.2% yeast extract is diluted with nutrient broth, plus 0.2% yeast extract is diluted with nutrient broth, plus 0.2% yeast extract to a suspension having 60% transmittance at a wavelength of 660 nm. This suspension is added to Difco nutrient agar supplemented with 2.0 g./l. Difco yeast extract at 47°C. to 48°C., to make a composition containing 33.2 ml. of the suspension per liter of agar. Forty ml. of this suspension is poured into 22.5 cm. x 22.5 cm. petri plates, and these plates are chilled and held at 4°C. until used (5 days maximum).
  • the TLC plate is removed and the assay plate incubated overnight at 37°C.
  • the additional bioactive spots present at R f 0.39 and R f 0.45 in the enzyme-treated reaction mixtures containing phenylacetyl thienamycin and N-(O-formyl)-l-mandeloyl thienamycin are due to thienamycin produced by amdohydrolase enzyme reaction.
  • a control containing buffer and enzyme alone produces no bioactive spots.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A method is disclosed for cleaving N-acylthienamycin compounds to yield thienamycin. The new method disclosed herein utilizes enzymes which are penicillin amidohydrolases to treat the starting compounds resulting in the antibiotic thienamycin.

Description

    BACKGROUND OF THE INVENTION:
  • The enzyme, penicillin amidohydrolase of bacterial or fungal origin is used on an industrial scale to catalyze the hydrolytic removal of the side chain of penicillin to give the nucleus 6-amino penicillanic acid (6-APA). This nucleus is the starting material for the synthesis of broad spectrum penicillins (semisynthetic) which are prepared by acylation of the amino group.
  • The International Commission of Enzyme Nomenclature has given the enzyme the systematic name, penicillin amidohydrolase (E.C. 3.5.1.11).
  • A new antibiotic is thienamycin, (U.S. Patent No. 3,950,357). The teachings of U.S. Patent No. 3,950,357 are incorporated herein by reference. N-acyl derivatives of thienamycin are unexpectedly cleaved by penicillin amidohydrolase.
  • SUMMARY OF THE INVENTION:
  • The present invention provides a new process for conversion of N-acyl-thienamycins to thienamycin.
  • According to the present invention, N-acyl- thienamycin, having the following structure:
    Figure imgb0001
    wherein R 1 and R2 are independently selected from the group consisting of hydrogen (R and R 2 are not both hydrogen) or an acyl group is contacted in an aqueous medium with enzymes which are capable of removing the N-acyl moiety in order to form thienamycin.
  • Thienamycin has the structure:
    Figure imgb0002
    Thienamycin is a valuable antibiotic which is active against both gram-positive and gram-negative bacteria.
  • More particularly, the enzymes utilized to remove the N-acyl moiety are penicillin amidohydrolases.
  • The preferred compounds of this invention are those wherein R1 is hydrogen and R2 is acyl. By the term "acyl" is meant the aliphatic and aromatic carboxylic acids including derivatives and analogs thereof such as thio analogs wherein the carbonyl oxygen is replaced by sulphur, diacyl radicals wherein R1 and R 2 are joined together; as well as the sulphur and phosphorous acyl analogs such as substituted sulfonyl-, sulfinyl-, and sulfenyl-radicals, and substituted P(III) and P(V) radicals such as the substituted phosphorous-, phosphoric-, phosphonous- and phosphonic radicals, respectively. Such acyl radicals of the present invention are further defined below.
  • DETAILED DESCRIPTION OF THE INVENTION:
  • The N-acyl derivatives may be prepared by any of the techniques well known in the art if the thienamycin has been isolated from the fermentation broth or solution. If the thienamycin has not been isolated from the fermentation broth, then the method of preparing the N-acyl-thienamycin is by reacting the appropriate acyl compound while the thienamycin is still in the broth or solution. Alternatively, the acyl group can be incorporated biosynthetically following supplementation of the fermentation broth with the parent acid or a derivative thereof. These derivatives, by virtue of their increased solubility in organic solvents and additional physical properties, provide alternate and more efficient routes for recovery of the thienamycin nucleus. Once the derivatized thienamycin is recovered from the broth or solution, it can be treated by the methods described in this invention in order to regenerate the thienamycin.
  • In the generic representation of the compounds of the present invention (I, above), the acyl radical represented by either R 1 or R2 can, inter alia, be substituted or unsubstituted aliphatic, aromatic or heterocyclic, araliphatic or heterocylylaliphatic carboxylic acid radical, a substituted or unsubstituted carbamyl radical or a carbothioic acid radical. One group of acyl radicals can be represented by the general formula:
    Figure imgb0003
    wherein X is 0 or S and R" represents a straight or branched chain alkyl or alkoxymethylene group containing from 5-10 carbon atoms, aryloxymethylene, typically comprising 6-10 carbon atoms. Such above-listed groups can be unsubstituted or can be substituted by radicals such as OH, SH, SR (R is i loweralkyl or aryl such as phenyl), alkyl or alkoxy groups having 1 to about 6 carbon atoms, halo, such as Cl, Br, F and I, cyano, carboxy, sulfamino, carbamoyl, sulfonyl, azido, amino, substituted amino such as alkylamino including quaternary ammonium wherein the alkyl group comprises 1-6 carbon atoms, haloalkyl such as trifluoromethyl, carboxyalkyl, carbamoylalkyl, N-substituted carbamoylalkyl, wherein the alkyl moiety of the foregoing four radicals comprises 1 to about 6 carbon atoms, amidino, guanidino, N-substituted guanidino, guanidino lower alkyl and the like. Representative examples of such acyl groups that might be mentioned are those wherein R" is benzyl, phenoxymethylene, p-hydroxybenzyl, n-amyl, n-heptyl, 3- or 4-nitrobenzyl, phenethyl,β,β-diphenylethyl, methyldiphenylmethyl, triphenylmethyl, 2-methoxyphenyl, 2,6-dimethoxyphenyl, 2,4,6-trimethoxyphenyl, D-4-N-benzoylamino-4-carboxy-n-butyl, p-aminobenzyl, o-aminobenzyl, m-aminobenzyl, p-dimethylaminobenzyl, 2-ethoxy-l-napthyl, 4-guanidinomethylphenyl, 4-guanidinomethylbenzyl, 4-guanidinobenzyl, 4-guanidinophenyl, 2,6-dimethoxy-4-guanidino, o-sulfobenzyl, p-carboxymethyl- benzyl, p-carbamoylmethylbenzyl, m-fluorobenzyl, m-bromobenzyl, p-chlorobenzyl, p-methoxybenzyl, 1-naphthylmethyl, 2-phenylvinyl, 2-phenylethynyl, phenyl, o-methoxyphenyl, o-chlorophenyl, o-phenylphenyl, and p-aminomethylbenzyl.
  • The preferred compounds that can be utilized in this invention that fit the above acyl radical description are phenylacetyl, p-hydroxyphenylacetyl, phenylglycyl, 2-thienylacetyl, phenoxyacetyl, N-propoxyacetyl and iso-butoxyacetyl.
  • The use of penicillin amidohydrolases to convert penicillins into 6-aminopenicillanic acid (6-APA) is known in the art. However, the use of penicillin amidohydrolases to remove the N-acyl side chains of N-acylated thienamycin is surprising. The process of this invention may be conducted by reacting the starting material of the general formula I with the enzyme extract from a cultured broth, the filtrate or fermentation product of the Escherichia coli culture or a powder of the enzyme in an aqueous solution. Alternatively, the enzyme may be immobilized by adsorption or chemical reaction to an insoluble supporting structure such as glass, cellulose or agarose, and used to hydrolyse the N-acylated thienamycin either by contacting it in suspension, or by the percolation of the acylated material through a bed of the immobilized enzyme preparation.
  • The enzyme is capable of removing N-acyl moietys which were present or produced in fermentation broths as well as those N-acyl groups introduced during isolation of the antibiotic or made by chemical synthesis techniques.
  • More particularly, the deacylation of N-acylated thienamycin takes place in the presence of an enzyme of the microorganism of the genus Escherichia coli which is able to remove the acyl moiety to provide the antibiotic thienamycin.
  • For the production of the amidohydrolase enzyme by cultivation of the above-mentioned microorganism, there may be used various culture media commonly employed for the cultivation of a microorganism. More specifically, glucose, sucrose, glycerol, starch, oils used for cultivation and the like as a carbon source and peptone, buillion, corn steep liquor, yeast extract, meat extract, fish meal, defatted soybean, wheat embryo and the like as a nitrogen source may be employed. If required, other additives may be employed in combination with the above. It is an advantage but not a necessity to include phenylacetic acid or its salts or derivatives in fermentation media.
  • As a cultivation method, Escherichia coli is usually shaken or agitated under aeration. Cultivation temperature may range from about 23-27°C. Cultivation period is usually 20-28 hours.
  • The amidohydrolase contained in the cultured broth or its extract may be utilized in the present process without any further purification. The amidohydrolase enzyme may be precipitated with appropriate solvents, salted out or dialyzed or otherwise purified. It may be used free in solution or immobilized on an appropriat surface.
  • A method utilized in the present invention is that of utilizing the whole cell amidohydrolase preparation. By this method, after cultivation, the culture is centrifuged to obtain the whole cells for subsequent reaction with the derivatized thienamycin.
  • The following are given for illustration purposes only and are not to be construed as limiting the scope of the present invention in any way.
  • EXAMPLE 1
  • Fifty ml. of 2.5% yeast extract containing 0.08% neutralized (with NaOH) phenylacetic acid in a 250-ml. Erlenmeyer flask is inoculated with a tube of lyophilized culture of MB-2929 (Escherichia coli N.C.I.B. 8743). This flask is shaken at 25°C. at 240 rpm for 24 hours. A 35-ml. portion is centrifuged at 7500 rpm for 15 minutes. The supernatant is discarded and the pellet resuspended in 18 ml. of distilled water. The solution is centrifuged at 7500 rpm for 15 minutes. The supernatant is discarded and the pellet taken up in 1 ml. 0.05M potassium phosphate buffer, pH 7.4 to yield a whole cell amidohydrolase preparation which is then stored at 0°C.
  • The following reaction mixtures are incubated 18 hours at 23°C.
    • 1. A 10-µl. portion of whole cell amidohydrolase preparation plus 30 µl. of an approximately 400-µg./ml. solution of N-phenylacetyl thienamycin.
    • 2. A 10-µl. portion of 0.05M potassium phosphate buffer, pH 7.4 plus 30 µl. of an approximately 400 µg./ml. solution of N-phenylacetyl thienamycin.
    • 3. A 10-µl. portion of whole cell amidohydrolase preparation plus 30 µl. of an approximately 1.3-mg./ml. solution of N-(O-formyl)-l-mandeloyl thienamycin.
    • 4. A 10-µl. portion of 0.05M potassium phosphate buffer, pH 7.4 plus 30 µl. of an approximately 1.3 mg./ml. solution of N-(O-formyl)-l-mandeloyl thienamycin.
    • 5. A 10-µl. portion of 0.05M potassium phosphate buffer pH 7.4 plus 30 ml. of a l-mg./ml. solution of thienamycin.
  • After the 18 hours of incubation, 1-µl. aliquots of the reaction mixtures are applied to a cellulose- coated TLC plate, which is developed in EtOH:H20 70:30. After air drying, the TLC plate is placed on a Staphylococcus aureus ATCC 6538P assay plate for five minutes.
  • The assay plates are prepared as follows: An overnight growth of the assay organism, Staphylococcus aureus ATCC 6538P, in nutrient broth plus 0.2% yeast extract is diluted with nutrient broth, plus 0.2% yeast extract is diluted with nutrient broth, plus 0.2% yeast extract to a suspension having 60% transmittance at a wavelength of 660 nm. This suspension is added to Difco nutrient agar supplemented with 2.0 g./l. Difco yeast extract at 47°C. to 48°C., to make a composition containing 33.2 ml. of the suspension per liter of agar. Forty ml. of this suspension is poured into 22.5 cm. x 22.5 cm. petri plates, and these plates are chilled and held at 4°C. until used (5 days maximum).
  • The TLC plate is removed and the assay plate incubated overnight at 37°C.
  • The following bioactive spots are observed:
    • 1. Rf 0.45 and 0.81;
    • 2. Rf 0.82;
    • 3. Rf 0.39 and 0.78;
    • 4. Rf 0.76
    • 5. Rf 0.39 - 0.45.
  • The additional bioactive spots present at Rf 0.39 and Rf 0.45 in the enzyme-treated reaction mixtures containing phenylacetyl thienamycin and N-(O-formyl)-l-mandeloyl thienamycin are due to thienamycin produced by amdohydrolase enzyme reaction. A control containing buffer and enzyme alone produces no bioactive spots.

Claims (5)

1. A method for the preparation of thienamycin havinq the structure:
Figure imgb0004
which comprises bringing into contact a compound having the formula:
Figure imgb0005
wherein R1 and R2 are independently selected from the group consisting of hydrogen and acyl radical, wherein R1 and R2 are not both hydrogen, with a penicillin amidohydrolase.
2. A process according to Claim 1 wherein the acyl radical is represented by the formula:
Figure imgb0006
wherein X is O or S and R" represents straight or branched chain alkyl or alkoxymethylene containing 5-10 carbon atoms; alkyl thio, aryl thio from 6-10 carbon atoms; aryloxymethylene containing 6-10 carbon atoms.
3. A process according to Claim 1 wherein the acyl radical is selected from the group consisting of phenylacetyl, p-hydroxyphenylacetyl, phenylglycyl, 2-thienylacetyl, phenoxyacetyl, N-propoxyacetyl and iso-butoxyacetyl.
4. A process according to Claim 1 wherein the penicillin amidohydrolase is 3.5.1.11 from Escherichia coli, N.C.I.B. 8743.
5. A process according to Claim 4 wherein the enzymatic cleaving is conducted in an aqueous medium.
EP78100699A 1977-08-19 1978-08-18 Enzymatic cleavage of n-acyl-thienamycins Expired EP0000931B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US05/825,883 US4162193A (en) 1977-08-19 1977-08-19 Enzymatic cleavage of N-acyl-thienamycins
US825883 1977-08-19

Publications (2)

Publication Number Publication Date
EP0000931A1 true EP0000931A1 (en) 1979-03-07
EP0000931B1 EP0000931B1 (en) 1982-04-14

Family

ID=25245138

Family Applications (1)

Application Number Title Priority Date Filing Date
EP78100699A Expired EP0000931B1 (en) 1977-08-19 1978-08-18 Enzymatic cleavage of n-acyl-thienamycins

Country Status (9)

Country Link
US (1) US4162193A (en)
EP (1) EP0000931B1 (en)
JP (1) JPS5446890A (en)
DE (1) DE2861737D1 (en)
DK (1) DK365478A (en)
ES (1) ES472701A1 (en)
IE (1) IE47315B1 (en)
IT (1) IT1106626B (en)
PT (1) PT68428A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02135843U (en) * 1988-11-08 1990-11-13

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3260653A (en) * 1959-04-18 1966-07-12 Bayer Ag Process for the production of 6-aminopenicillanic acid
DE2652678A1 (en) * 1975-11-24 1977-06-02 Merck & Co Inc ANTIBIOTICA AND METHOD OF MANUFACTURING THE SAME
NL7800958A (en) * 1977-02-11 1978-08-15 Merck & Co Inc ANTIBIOTIC DESACETYL-DIHYDRO 890 A9, METHOD FOR PREPARING IT AND PHARMACEUTICAL PREPARATION CONTAINING THIS ANTIBIOTIC.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH475284A (en) * 1963-11-19 1969-07-15 Ciba Geigy Process for the preparation of deacetyl-7-aminocephalosporanic acid
JPS5417030B2 (en) * 1972-12-06 1979-06-27
GB1474519A (en) * 1973-05-14 1977-05-25
JPS5713280B2 (en) * 1974-03-11 1982-03-16
US3950357A (en) * 1974-11-25 1976-04-13 Merck & Co., Inc. Antibiotics

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3260653A (en) * 1959-04-18 1966-07-12 Bayer Ag Process for the production of 6-aminopenicillanic acid
DE2652678A1 (en) * 1975-11-24 1977-06-02 Merck & Co Inc ANTIBIOTICA AND METHOD OF MANUFACTURING THE SAME
NL7800958A (en) * 1977-02-11 1978-08-15 Merck & Co Inc ANTIBIOTIC DESACETYL-DIHYDRO 890 A9, METHOD FOR PREPARING IT AND PHARMACEUTICAL PREPARATION CONTAINING THIS ANTIBIOTIC.

Also Published As

Publication number Publication date
JPS5446890A (en) 1979-04-13
IE781674L (en) 1979-02-19
ES472701A1 (en) 1979-02-16
JPS6210639B2 (en) 1987-03-07
IT7850747A0 (en) 1978-08-16
EP0000931B1 (en) 1982-04-14
IT1106626B (en) 1985-11-11
DE2861737D1 (en) 1982-05-27
DK365478A (en) 1979-02-20
US4162193A (en) 1979-07-24
PT68428A (en) 1978-09-01
IE47315B1 (en) 1984-02-22

Similar Documents

Publication Publication Date Title
US4526783A (en) Antibiotic from S. clavuligerus
US3239394A (en) Process for producing 7-amino-cephalosporanic acid
CA1049532A (en) Antibiotics
US4162193A (en) Enzymatic cleavage of N-acyl-thienamycins
US6156534A (en) Synthesis of β-lactam antibacterials using soluble side chain esters and enzyme acylase
EP0000932B1 (en) Production of n-acyl-thienamycins
EP0001567B1 (en) Thienamycin related antibiotics ps-6 and ps-7, process for their production and compositions containing them
Ito et al. A novel β-lactamase inhibitor, SF-2103 A produced by a Streptomyces
EP0052974B1 (en) Improvements in enzymatic deesterification
US4587333A (en) Cephalosporins and their production
CS269952B2 (en) Method of enduracidine production
US4656288A (en) Antibiotics, their production and use
US3899394A (en) Production of antibacterial agents
US3905868A (en) Enzymatic deacylation of benzyl- and phenoxymethylpenicillin tetrazoles
CA1238594A (en) Antibiotics, tan-558, their production and use
US4205068A (en) β-Lactamase inhibitor EM4615
EP0046596B1 (en) Antibiotic pa-39504-x3, process for its production and pharmaceutical compositions
Serizawa et al. Enzymatic conversion of cephamycin C by D-amino acid oxidase from Trigonopsis variabilis
EP0079244B1 (en) Pluracidomycin b,c, and d and analogs thereof, their production and a microorganism for use therein
US3616223A (en) Penicillin intermediate
US4448723A (en) Antibiotics PA-41746-B and C
US4667027A (en) Cephem compounds and their production
US4468350A (en) KA-6643-Series antibiotics, process for producing same and medical composition containing same
US3717548A (en) Method for preparing aminocyclohexylpenicillin
US3088880A (en) 6-aminopenicillanic acid amide production

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): BE CH DE FR GB LU NL SE

17P Request for examination filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): BE CH DE FR GB LU NL SE

REF Corresponds to:

Ref document number: 2861737

Country of ref document: DE

Date of ref document: 19820527

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19820831

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19830630

Year of fee payment: 6

Ref country code: BE

Payment date: 19830630

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19830706

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19840819

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Effective date: 19890831

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19910606

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19910628

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19910701

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19910826

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19910831

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19920818

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Effective date: 19920831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19930301

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19920818

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19930430

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19930501

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

EUG Se: european patent has lapsed

Ref document number: 78100699.4

Effective date: 19850612

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT